Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1995 Jul 3;92(14):6254-8.
doi: 10.1073/pnas.92.14.6254.

Synergy between T-cell immunity and inhibition of paracrine stimulation causes tumor rejection

Affiliations

Synergy between T-cell immunity and inhibition of paracrine stimulation causes tumor rejection

L P Seung et al. Proc Natl Acad Sci U S A. .

Abstract

During tumor progression, variants may arise that grow more vigorously. The fate of such variants depends upon the balance between aggressiveness of the variant and the strength of the host immunity. Although enhancing host immunity to cancer is a logical objective, eliminating host factors necessary for aggressive growth of the variant should also be considered. The present study illustrates this concept in the model of a spontaneously occurring, progressively growing variant of an ultraviolet light-induced tumor. The variant produces chemotactic factors that attract host leukocytes and is stimulated in vitro by defined growth factors that can be produced or induced by leukocytes. This study also shows that CD8+ T-cell immunity reduces the rate of tumor growth; however, the variant continues to grow and kills the host. Treatment with a monoclonal anti-granulocyte antibody that counteracts the infiltration of the tumor cell inoculum by non-T-cell leukocytes did not interfere with the CD8+ T-cell-mediated immune response but resulted in rejection of the tumor challenge, indicating a synergy between CD8+ T-cell-mediated immunity and the inhibition of paracrine stimulation.

PubMed Disclaimer

References

    1. Curr Opin Immunol. 1989-1990;2(5):689-92 - PubMed
    1. Cancer Res. 1990 Jul 1;50(13):3851-8 - PubMed
    1. J Exp Med. 1990 Oct 1;172(4):1217-24 - PubMed
    1. J Immunol. 1991 Jul 1;147(1):22-8 - PubMed
    1. Cell. 1992 Dec 24;71(7):1093-102 - PubMed

Publication types

MeSH terms

Substances